|
16 Dec 2021 |
Valneva Announces Positive Homologous Booster Data for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
|
|
15 Dec 2021 |
European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
|
|
15 Dec 2021 |
Sumitomo Dainippon Pharma Oncology Provides Update on Phase 3 WIZARD 201G Study of Ombipepimut-S Emulsion (DSP-7888) in Patients with Recurrent or Progressive Glioblastoma
|
|
15 Dec 2021 |
Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation
|
|
11 Dec 2021 |
Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update
|
|
08 Dec 2021 |
I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease
|
|
07 Dec 2021 |
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
|
|
06 Dec 2021 |
Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate
|
|
06 Dec 2021 |
Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses
|
|
03 Dec 2021 |
Valneva Confirms Initiation of Rolling Review with EMA and Provides Updates on its COVID-19 Vaccine Program VLA2001
|
|
02 Dec 2021 |
Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates
|
|
02 Dec 2021 |
VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults
|
|
02 Dec 2021 |
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
|
|
27 Nov 2021 |
Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
|
|
22 Nov 2021 |
Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
|
|
21 Nov 2021 |
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
|
|
21 Nov 2021 |
Akston Biosciences Doses First Subjects in Phase II Clinical Trial in India of Second-Generation COVID-19 Vaccine
|
|
17 Nov 2021 |
Daiichi Sankyo Initiates Phase 2 Trial of mRNA Vaccine Against COVID-19 (DS-5670) in Japan
|
|
16 Nov 2021 |
Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate
|
|
14 Nov 2021 |
AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer’s Vaccine Generates a Potent Immune Response
|
|
12 Nov 2021 |
Recbio Announces Promising Preliminary Results From First-in-Human Study of a COVID-19 Vaccine Candidate With Novel Adjuvant BFA03
|
|
11 Nov 2021 |
Inventprise Announces Investment of up to $90 Million to Advance its 25 Valent Pneumococcal Conjugate Vaccine Candidate into Proof-of-Concept Clinical Trials
|
|
10 Nov 2021 |
Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2
|
|
05 Nov 2021 |
Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years
|
|
04 Nov 2021 |
Uvax-2129, a Recombinant Protein Nanoparticle Vaccine, Uvax Bio’s Answer to COVID-19, Shows Great Promise Against Variants of Concern
|
